4/A: Matthew E. Korenberg Reports Stock Option Grant in Palvella Therapeutics

Matthew E. Korenberg, CFO and Treasurer of Palvella Therapeutics, reports the acquisition of incentive and non-qualified stock options.

Summary

• Matthew E. Korenberg, CFO and Treasurer of Palvella Therapeutics, filed an amended Form 4 on February 10, 2025, to reflect a name change.
• The report details the acquisition of 5,373 incentive stock options and 123,559 non-qualified stock options on February 5, 2025, both with an exercise price of $14.76.
• The options vest in equal monthly tranches over 48 months and expire on February 5, 2035.
• Following the reported transaction, Korenberg directly owns 5,373 incentive stock options and 123,559 non-qualified stock options.

Sentiment

Score: 6

Explanation: The document is a routine disclosure of stock option grants, which is neither particularly positive nor negative. It suggests continued alignment of management with shareholder interests.

Positives

• The grant of stock options to the CFO and Treasurer could incentivize him to improve the company's performance.

Industry Context

Stock option grants are a common form of executive compensation in the pharmaceutical industry, aligning management's interests with those of shareholders.

Stakeholder Impact

• The stock option grant could potentially align the CFO's interests with those of shareholders, encouraging value creation.

Key Dates